Patents by Inventor Susan E. Alters

Susan E. Alters has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BINDING FUSION PROTEINS, BINDING FUSION PROTEIN-DRUG CONJUGATES, XTEN-DRUG CONJUGATES AND METHODS OF MAKING AND USING SAME
    Publication number: 20130165389
    Abstract: The present invention relates to binding fusion protein compositions comprising targeting moieties linked to extended recombinant polypeptide (XTEN), binding fusion protein-drug conjugate compositions, and XTEN-drug conjugate compositions, isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of diseases, disorders, and conditions.
    Type: Application
    Filed: September 28, 2012
    Publication date: June 27, 2013
    Applicant: Amunix Operating Inc.
    Inventors: Volker Schellenberger, Joshua Silverman, Chia-wei Wang, Benjamin Spink, Willem P. Stemmer, Susan E. Alters, Nathan Geething
  • Biological markers for evaluating therapeutic treatment of inflammatory and autoimmune disorders
    Patent number: 6753135
    Abstract: Novel biological markers indicative of the action of an anti-inflammatory or immunosuppressive drug can be used to evaluate drug efficacy and compare local and systemic drug effects. They can also aid in comparison of different drugs, doses, and delivery routes. The biological markers include cell populations, cell surface antigen expression levels, and soluble factor concentrations. Measurement values of the novel biomarkers were shown to change significantly in allergic, atopic asthmatic, and healthy subjects after administration of prednisone.
    Type: Grant
    Filed: September 20, 2001
    Date of Patent: June 22, 2004
    Assignee: SurroMed, Inc.
    Inventors: Susan E. Alters, Karen L. Cheal, Aaron B. Kantor
  • Biological markers for evaluating therapeutic treatment of inflammatory and autoimmune disorders
    Publication number: 20020072484
    Abstract: Novel biological markers indicative of the action of an anti-inflammatory or immunosuppressive drug can be used to evaluate drug efficacy and compare local and systemic drug effects. They can also aid in comparison of different drugs, doses, and delivery routes. The biological markers include cell populations, cell surface antigen expression levels, and soluble factor concentrations. Measurement values of the novel biomarkers were shown to change significantly in allergic, atopic asthmatic, and healthy subjects after administration of prednisone.
    Type: Application
    Filed: September 20, 2001
    Publication date: June 13, 2002
    Inventors: Susan E. Alters, Karen L. Cheal, Aaron B. Kantor